Exosomal microRNAs from longitudinal liquid biopsies for the prediction of response to induction chemotherapy in high-risk neuroblastoma patients: A proof of concept SIOPEN study

Martina Morini, Davide Cangelosi, Daniela Segalerba, Danilo Marimpietri, Federica Raggi, Aurora Castellano, Doriana Fruci, Jaime Font De Mora, Adela Cañete, Yania Yáñez, Virginie Viprey, Maria Valeria Corrias, Barbara Carlini, Annalisa Pezzolo, Gudrun Schleiermacher, Katia Mazzocco, Ruth Ladenstein, Angela Rita Sementa, Massimo Conte, Alberto GaraventaSusan Burchill, Roberto Luksch, Maria Carla Bosco, Alessandra Eva, Luigi Varesio

Research output: Contribution to journalArticle

Abstract

Despite intensive treatment, 50% of children with high-risk neuroblastoma (HR-NB) succumb to their disease. Progression through current trials evaluating the efficacy of new treatments for children with HR disease usually depends on an inadequate response to induction chemotherapy, assessed using imaging modalities. In this study, we sought to identify circulating biomarkers that might be detected in a simple blood sample to predict patient response to induction chemotherapy. Since exosomes released by tumor cells can drive tumor growth and chemoresistance, we tested the hypothesis that exosomal microRNA (exo-miRNAs) in blood might predict response to induction chemotherapy. The exo-miRNAs expression profile in plasma samples collected from children treated in HR-NBL-1/SIOPEN before and after induction chemotherapy was compared to identify a three exo-miRs signature that could discriminate between poor and good responders. Exo-miRNAs expression also provided a chemoresistance index predicting the good or poor prognosis of HR-NB patients.

Original languageEnglish
Article number1476
JournalCancers
Volume11
Issue number10
DOIs
Publication statusPublished - Oct 2019

Fingerprint

Induction Chemotherapy
MicroRNAs
Neuroblastoma
Biopsy
Exosomes
Neoplasms
Biomarkers
Growth
Therapeutics

Keywords

  • Chemotherapy response
  • Exosomes
  • Liquid biopsy
  • MiRNA
  • Neuroblastoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{72fe3629bec84ebe9694673a057223a1,
title = "Exosomal microRNAs from longitudinal liquid biopsies for the prediction of response to induction chemotherapy in high-risk neuroblastoma patients: A proof of concept SIOPEN study",
abstract = "Despite intensive treatment, 50{\%} of children with high-risk neuroblastoma (HR-NB) succumb to their disease. Progression through current trials evaluating the efficacy of new treatments for children with HR disease usually depends on an inadequate response to induction chemotherapy, assessed using imaging modalities. In this study, we sought to identify circulating biomarkers that might be detected in a simple blood sample to predict patient response to induction chemotherapy. Since exosomes released by tumor cells can drive tumor growth and chemoresistance, we tested the hypothesis that exosomal microRNA (exo-miRNAs) in blood might predict response to induction chemotherapy. The exo-miRNAs expression profile in plasma samples collected from children treated in HR-NBL-1/SIOPEN before and after induction chemotherapy was compared to identify a three exo-miRs signature that could discriminate between poor and good responders. Exo-miRNAs expression also provided a chemoresistance index predicting the good or poor prognosis of HR-NB patients.",
keywords = "Chemotherapy response, Exosomes, Liquid biopsy, MiRNA, Neuroblastoma",
author = "Martina Morini and Davide Cangelosi and Daniela Segalerba and Danilo Marimpietri and Federica Raggi and Aurora Castellano and Doriana Fruci and {De Mora}, {Jaime Font} and Adela Ca{\~n}ete and Yania Y{\'a}{\~n}ez and Virginie Viprey and Corrias, {Maria Valeria} and Barbara Carlini and Annalisa Pezzolo and Gudrun Schleiermacher and Katia Mazzocco and Ruth Ladenstein and Sementa, {Angela Rita} and Massimo Conte and Alberto Garaventa and Susan Burchill and Roberto Luksch and Bosco, {Maria Carla} and Alessandra Eva and Luigi Varesio",
year = "2019",
month = "10",
doi = "10.3390/cancers11101476",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "10",

}

TY - JOUR

T1 - Exosomal microRNAs from longitudinal liquid biopsies for the prediction of response to induction chemotherapy in high-risk neuroblastoma patients

T2 - A proof of concept SIOPEN study

AU - Morini, Martina

AU - Cangelosi, Davide

AU - Segalerba, Daniela

AU - Marimpietri, Danilo

AU - Raggi, Federica

AU - Castellano, Aurora

AU - Fruci, Doriana

AU - De Mora, Jaime Font

AU - Cañete, Adela

AU - Yáñez, Yania

AU - Viprey, Virginie

AU - Corrias, Maria Valeria

AU - Carlini, Barbara

AU - Pezzolo, Annalisa

AU - Schleiermacher, Gudrun

AU - Mazzocco, Katia

AU - Ladenstein, Ruth

AU - Sementa, Angela Rita

AU - Conte, Massimo

AU - Garaventa, Alberto

AU - Burchill, Susan

AU - Luksch, Roberto

AU - Bosco, Maria Carla

AU - Eva, Alessandra

AU - Varesio, Luigi

PY - 2019/10

Y1 - 2019/10

N2 - Despite intensive treatment, 50% of children with high-risk neuroblastoma (HR-NB) succumb to their disease. Progression through current trials evaluating the efficacy of new treatments for children with HR disease usually depends on an inadequate response to induction chemotherapy, assessed using imaging modalities. In this study, we sought to identify circulating biomarkers that might be detected in a simple blood sample to predict patient response to induction chemotherapy. Since exosomes released by tumor cells can drive tumor growth and chemoresistance, we tested the hypothesis that exosomal microRNA (exo-miRNAs) in blood might predict response to induction chemotherapy. The exo-miRNAs expression profile in plasma samples collected from children treated in HR-NBL-1/SIOPEN before and after induction chemotherapy was compared to identify a three exo-miRs signature that could discriminate between poor and good responders. Exo-miRNAs expression also provided a chemoresistance index predicting the good or poor prognosis of HR-NB patients.

AB - Despite intensive treatment, 50% of children with high-risk neuroblastoma (HR-NB) succumb to their disease. Progression through current trials evaluating the efficacy of new treatments for children with HR disease usually depends on an inadequate response to induction chemotherapy, assessed using imaging modalities. In this study, we sought to identify circulating biomarkers that might be detected in a simple blood sample to predict patient response to induction chemotherapy. Since exosomes released by tumor cells can drive tumor growth and chemoresistance, we tested the hypothesis that exosomal microRNA (exo-miRNAs) in blood might predict response to induction chemotherapy. The exo-miRNAs expression profile in plasma samples collected from children treated in HR-NBL-1/SIOPEN before and after induction chemotherapy was compared to identify a three exo-miRs signature that could discriminate between poor and good responders. Exo-miRNAs expression also provided a chemoresistance index predicting the good or poor prognosis of HR-NB patients.

KW - Chemotherapy response

KW - Exosomes

KW - Liquid biopsy

KW - MiRNA

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=85073429184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073429184&partnerID=8YFLogxK

U2 - 10.3390/cancers11101476

DO - 10.3390/cancers11101476

M3 - Article

AN - SCOPUS:85073429184

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

M1 - 1476

ER -